Inflammatory and immune responses play important roles following ischaemic stroke. Inflammatory responses contribute to damage and also contribute to repair. Injury to tissue triggers an immune response. This is initiated through activation of the innate immune system. In stroke there is microglial activation. This is followed by an influx of lymphocytes and macrophages into the brain, triggered by production of pro-inflammatory cytokines. This inflammatory response contributes to further tissue injury. There is also a systemic immune response to stroke, and there is a degree of immunosuppression that may contribute to the stroke patient's risk of infection. This immunosuppressive response may also be protective, with regulatory lymphocytes producing cytokines and growth factors that are neuroprotective. The specific targets of the immune response after stroke are not known, and the details of the immune and inflammatory responses are only partly understood. The role of inflammation and immune responses after stroke is twofold. The immune system may contribute to damage after stroke, but may also contribute to repair processes. The possibility that some of the immune response after stroke may be neuroprotective is exciting and suggests that deliberate enhancement of these responses may be a therapeutic option.
Ni ChoileainNRedmondHP: Cell response to surgery. Arch Surg2006; 141:1132–40.
2.
LevyRMPrinceJMYangRSystemic inflammation and remote organ damage following bilateral femur fracture requires Toll-like receptor 4. Am J Physiol Regul Integr Comp Physiol2006; 291:R970–6.
3.
ZhaiYShenXDHancockWWCXCR3+CD4+ T cells mediate innate immune function in the pathophysiology of liver ischemia/reperfusion injury. J Immunol2006; 176:6313–22.
BeutlerB: Innate immunity: an overview. Mol Immunol2004; 40: 845–59.
6.
MedzhitovRJanewayCAJr: Innate immunity: the virtues of a nonclonal system of recognition. Cell1997; 91:295–8.
7.
CoutinhoAPoltorackA: Innate immunity: from lymphocyte mitogens to Toll-like receptors and back. Curr Opin Immunol2003; 15: 599–602.
8.
AkiraSUematsuSTakeuchiO: Pathogen recognition and innate immunity. Cell2006; 124:783–801.
9.
LoDFengLLiLIntegrating innate and adaptive immunity in the whole animal. Immunol Rev1999; 169:225–39.
10.
PalmNWMedzhitovR: Not so fast: adaptive suppression of innate immunity. Nat Med2007; 13:1142–4.
11.
KoenigWKhuseyinovaN: Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol2007; 27:15–26.
12.
EsperRJNordabyRAVilarinoJOParaganoACacharronJLMachadoRA: Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol2006; 5:4.
13.
CroceKLibbyP: Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol2007; 14:55–61.
14.
HanssonGKLibbyP: The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol2006; 6:508–19.
15.
XuQBOberhuberGGruschwitzMWickG: Immunology of atherosclerosis: cellular composition and major histocompatibility complex class II antigen expression in aortic intima, fatty streaks, and atherosclerotic plaques in young and aged human specimens. Clin Immunol Immunopathol1990; 56:344–59.
16.
JonassonLHolmJSkalliOBondjersGHanssonGK: Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis1986; 6:131–8.
17.
KobayashiKLopezLRShoenfeldYMatsuuraE: The role of innate and adaptive immunity to oxidized low-density lipoprotein in the development of atherosclerosis. Ann NY Acad Sci2005; 1051:442–54.
18.
MorAPlanerDLuboshitsGRole of naturally occurring CD4+CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol2007; 27:893–900.
19.
van PuijveldeGHHauerADde VosPInduction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation2006; 114:1968–76.
20.
MollerFAndersenCBNielsenLB: Adhesion of T and B lymphocytes to mouse atherosclerotic aortas: association with lesion topology and VCAM-1 expression. Scand J Clin Lab Invest2005; 65:559–70.
21.
GalkinaEKadlASandersJVarugheseDSarembockIJLeyK: Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med2006; 203:1273–82.
22.
ColobranRPujol-BorrellRArmengolMPJuanM: The chemokine network. I. How the genomic organization of chemokines contains clues for deciphering their functional complexity. Clin Exp Immunol2007; 148:208–17.
23.
GalkinaEHarryBLLudwigACXCR6 promotes atherosclerosis by supporting T-cell homing, interferon-gamma production, and macrophage accumulation in the aortic wall. Circulation2007; 116:1801–11.
24.
HellerEALiuETagerAMChemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation2006; 113:2301–12.
25.
MachFSchonbeckUSukhovaGKFunctional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA1997; 94: 1931–6.
26.
SchonbeckULibbyP: CD40 signaling and plaque instability. Circ Res2001; 89:1092–103.
27.
MachFSchonbeckULibbyP: CD40 signaling in vascular cells: a key role in atherosclerosis?Atherosclerosis1998; 137(Suppl.): S89–95.
28.
TedguiAMallatZ: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev2006; 86:515–81.
29.
TanneDBenderlyMGoldbourtUC-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease. Stroke2006; 37:1720–4.
30.
ZhuYCCuiLYHuaBLPanJQ: Correlation between fibrinogen level and cerebral infarction. Chin Med Sci J2006; 21:167–70.
31.
AonoYOhkuboTKikuyaMPlasma fibrinogen, ambulatory blood pressure, and silent cerebrovascular lesions. The Ohasama Study. Arterioscler Thromb Vasc Biol2007; 27:963–8.
32.
ElkindMS: Inflammation, atherosclerosis, and stroke. Neurologist2006; 12:140–8.
33.
With NotoATBogebergMEAmiralJVissacAMHansenJB: Endothelial dysfunction and systemic inflammation in persons with echolucent carotid plaques. Thromb Haemost2006; 96:53–9.
34.
McCollBWRothwellNJAllanSM: Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci2007; 27:4403–12.
SimpsonE: A historical perspective on immunological privilege. Immunol Rev2006; 213:12–22.
37.
NimmerjahnAKirchhoffFHelmchenF: Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science2005; 308:1314–8.
38.
MelchiorBPuntambekarSSCarsonMJ: Microglia and the control of auto reactive T cell responses. Neurochem Int2006; 49:145–53.
39.
BaileySLCarpentierPAMcMahonEJBegolkaWSMillerSD: Innate and adaptive immune responses of the central nervous system. Crit Rev Immunol2006; 26:149–88.
40.
LucasSMRothwellNJGibsonRM: The role of inflammation in CNS injury and disease. Br J Pharmacol2006; 147(Suppl. 1): S232–40.
41.
KimWKAlvarezXFisherJCD163 identifies perivascular macrophages in normal and viral encephalitic brains and potential precursors to perivascular macrophages in blood. Am J Pathol2006; 168:822–34.
42.
WangPYKaoCHMuiMYWangSJ: Leukocyte infiltration in acute hemispheric ischemic stroke. Stroke1993; 24:236–40.
FabriekBOZwemmerJNTeunissenCEIn vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. J Neuroimmunol2005; 161:190–4.
45.
KarikoKWeissmanDWelshFA: Inhibition of toll-like receptor and cytokine signaling - a unifying theme in ischemic tolerance. J Cereb Blood Flow Metab2004; 24:1288–304.
46.
MollenKPAnandRJTsungAPrinceJMLevyRMBilliarTR: Emerging paradigm: Toll-like receptor 4-sentinel for the detection of tissue damage. Shock2006; 26:430–7.
47.
MiyakeK: Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol2007; 19:3–10.
48.
AloisiF: Immune function of microglia. Glia2001; 36:165–79.
49.
OlsonJKMillerSD: Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol2004; 173:3916–24.
50.
BsibsiMRavidRGvericDvan NoortJM: Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol2002; 61:1013–21.
51.
FarinaCAloisiFMeinlE: Astrocytes are active players in cerebral innate immunity. Trends Immunol2007; 28:138–45.
52.
KonatGWKielianTMarriottI: The role of Toll-like receptors in CNS response to microbial challenge. J Neurochem2006; 99:1–12.
53.
CarpentierPABegolkaWSOlsonJKElhofyAKarpusWJMillerSD: Differential activation of astrocytes by innate and adaptive immune stimuli. Glia2005; 49:360–74.
PatersonHMMurphyTJPurcellEJInjury primes the innate immune system for enhanced Toll-like receptor reactivity. J Immunol2003; 171:1473–83.
56.
LindsbergPJCarpenOPaetauAKarjalainen-LindsbergMLKasteM: Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation1996; 94:939–45.
57.
ZhangZChoppMPowersC: Temporal profile of microglial response following transient (2 h) middle cerebral artery occlusion. Brain Res1997; 744:189–98.
58.
PriceCJWangDMenonDKIntrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. Stroke2006; 37:1749–53.
59.
ZhangRChoppMZhangZJiangNPowersC: The expression of P- and E-selectins in three models of middle cerebral artery occlusion. Brain Res1998; 785:207–14.
60.
ArumugamTVGrangerDNMattsonMP: Stroke and T-cells. Neuromol Med2005; 7:229–42.
61.
HuangJUpadhyayUMTamargoRJ: Inflammation in stroke and focal cerebral ischemia. Surg Neurol2006; 66:232–45.
62.
GarciaJH: The neuropathology of stroke. Hum Pathol1975; 6:583–98.
63.
NilupulPMMaHKArakawaSInflammation following stroke. J Clin Neurosci2006; 13:1–8.
64.
SchroeterMJanderSWitteOWStollG: Local immune responses in the rat cerebral cortex after middle cerebral artery occlusion. J Neuroimmunol1994; 55:195–203.
65.
SalehASchroeterMJonkmannsCHartungHPModderUJanderS: In vivo MRI of brain inflammation in human ischaemic stroke. Brain2004; 127:1670–7.
66.
StrbianDKarjalainen-LindsbergMLTatlisumakTLindsbergPJ: Cerebral mast cells regulate early ischemic brain swelling and neutrophil accumulation. J Cereb Blood Flow Metab2006; 26:605–12.
67.
RostromBLinkB: Oligoclonal immunoglobulins in cerebrospinal fluid in acute cerebrovascular disease. Neurology1981; 31:590–6.
68.
SuzukiSKelleyREReyes-IglesiasYAlfonsoVMDietrichWD: Cerebrospinal fluid and peripheral white blood cell response to acute cerebral ischemia. South Med J1995; 88:819–24.
69.
ZarembaJIlkowskiJLosyJ: Serial measurements of levels of the chemokines CCL2, CCL3 and CCL5 in serum of patients with acute ischaemic stroke. Folia Neuropathol2006; 44:282–9.
70.
DimitrijevicOBStamatovicSMKeepRFAndjelkovicAV: Absence of the chemokine receptor CCR2 protects against cerebral ischemia/reperfusion injury in mice. Stroke2007; 38:1345–53.
71.
JauchECLindsellCBroderickJFaganSCTilleyBCLevineSR: Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke2006; 37:2508–13.
72.
HerrmannMVosPWunderlichMTde BruijnCHLamersKJ: Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke2000; 31:2670–7.
73.
WunderlichMTEbertADKratzTGoertlerMJostSHerrmannM: Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke1999; 30:1190–5.
74.
LeiraRRodriguez-YanezMCastellanosMHyperthermia is a surrogate marker of inflammation-mediated cause of brain damage in acute ischaemic stroke. J Intern Med2006; 260:343–9.
75.
VilaNCastilloJDavalosAChamorroA: Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke2000; 31:2325–9.
76.
ChamorroAUrraXPlanasAM: Infection after acute ischemic stroke. A manifestation of brain-induced immunodepression. Stroke2007; 38:1097–103.
77.
DirnaglUKlehmetJBraunStroke-induced immunodepression: experimental evidence and clinical relevance. Stroke2007; 38:770–3.
78.
PrassKBraunJSDirnaglUMeiselCMeiselA: Stroke propagates bacterial aspiration to pneumonia in a model of cerebral ischemia. Stroke2006; 37:2607–12.
79.
PrassKMeiselCHoflichCStroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med2003; 198:725–36.
80.
MeiselCSchwabJMPrassKMeiselADirnaglU: Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci2005; 6:775–86.
81.
KlavaAWindsorACFarmerySMInterleukin-10. A role in the development of postoperative immunosuppression. Arch Surg1997; 132:425–9.
82.
GiannoudisPVSmithRMPerrySLWindsorAJDicksonRABellamyMC: Immediate IL-10 expression following major orthopaedic trauma: relationship to anti-inflammatory response and subsequent development of sepsis. Intens Care Med2000; 26:1076–81.
83.
UedaTTakeyamaYYasudaTImmunosuppression in patients with severe acute pancreatitis. J Gastroenterol2006; 41:779–84.
84.
Schulte-HerbruggenOKlehmetJQuarcooDMeiselCMeiselA: Mouse strains differ in their susceptibility to poststroke infections. Neuroimmunomodulation2006; 13:13–8.
85.
ChamorroAHorcajadaJPObachVThe early systemic prophylaxis of infection after stroke study: a randomized clinical trial. Stroke2005; 36:1495–500.
86.
ChamorroAUrraXPlanasAM: Infection after acute ischemic stroke: a manifestation of brain-induced immunodepression. Stroke2007; 38:1097–103.
87.
EmsleyHCSmithCJGavinCMAn early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol2003; 139:93–101.
88.
RallidisLSVikelisMPanagiotakosDBInflammatory markers and in-hospital mortality in acute ischaemic stroke. Atherosclerosis2006; 189:193–7.
89.
MarquardtLRufAMansmannUInflammatory response after acute ischemic stroke. J Neurol Sci2005; 236:65–71.
90.
SmithCJEmsleyHCGavinCMPeak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol2004; 4:2.
91.
SmithCJEmsleyHCVailAVariability of the systemic acute phase response after ischemic stroke. J Neurol Sci2006; 251:77–81.
92.
SchmidtRSchmidtHPichlerMC-reactive protein, carotid atherosclerosis, and cerebral small-vessel disease: results of the Austrian Stroke Prevention Study. Stroke2006; 37:2910–6.
93.
BosMJSchipperCMKoudstaalPJWittemanJCHofmanABretelerMM: High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam Study. Circulation2006; 114:1591–8.
94.
WoodwardMLoweGDCampbellDJAssociations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke2005; 36:2143–7.
95.
DiNMPapaF: Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke2002; 33:1763–71.
96.
PurroyFMontanerJMolinaCAC-reactive protein predicts further ischemic events in transient ischemic attack patients. Acta Neurol Scand2007; 115:60–6.
97.
ElkindMSTaiWCoatesKPaikMCSaccoRL: High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med2006; 166:2073–80.
98.
PedersenEDWaje-AndreassenUVedelerCAAamodtGMollnesTE: Systemic complement activation following human acute ischaemic stroke. Clin Exp Immunol2004; 137:117–22.
99.
MoccoJWilsonDAKomotarRJAlterations in plasma complement levels after human ischemic stroke. Neurosurgery2006; 59:28–33.
100.
AtkinsonCZhuHQiaoFComplement-dependent P-selectin expression and injury following ischemic stroke. J Immunol2006; 177:7266–74.
101.
YipHKChenSSLiuJSSerial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation. Stroke2004; 35:1683–7.
102.
Fateh-MoghadamSHtunPTomandlBHyperresponsiveness of platelets in ischemic stroke. Thromb Haemost2007; 97:974–8.
103.
MarquardtLRufAMansmannUCourse of platelet activation markers after ischemic stroke. Stroke2002; 33:2570–4.
104.
TarkowskiEEkelundPTarkowskiA: Increased systemic T-lymphocyte reactivity in patients with established stroke. J Clin Lab Immunol1991; 35: 171–6.
105.
FerrareseCMascarucciPZoiaCIncreased cytokine release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab1999; 19:1004–9.
106.
GarlichsCDKozinaSFateh-MoghadamSUp-regulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke2003; 34:1412–8.
107.
OffnerHSubramanianSParkerSMAfentoulisMEVandenbarkAAHurnPD: Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab2006; 26:654–65.
108.
TangYXuHDuXGene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J Cereb Blood Flow Metab2006; 26:1089–102.
109.
DuXTangYXuHGenomic profiles for human peripheral blood T cells, B cells, natural killer cells, monocytes, and polymorphonuclear cells: comparisons to ischemic stroke, migraine, and Tourette syndrome. Genomics2006; 87:693–703.
110.
CzlonkowskaACyrtaBKorlakJ: Immunological observations on patients with acute cerebral vascular disease. J Neurol Sci1979; 43:455–64.
111.
WolkKHoflichCZuckermann-BeckerHDockeWDVolkHDSabatR: Reduced monocyte CD86 expression in postinflammatory immunodeficiency. Crit Care Med2007; 35:458–67.
112.
ChatilaTA: Role of regulatory T cells in human diseases. J Allergy Clin Immunol2005; 116:949–59.
113.
ZieglerSF: FOXP3: of mice and men. Annu Rev Immunol2006; 24:209–26.
114.
ChamorroAAmaroSVargasMInterleukin 10, monocytes and increased risk of early infection in ischaemic stroke. J Neurol Neurosurg Psychiatry2006; 77:1279–81.
115.
OffnerHSubramanianSParkerSMSplenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol2006; 176:6523–31.
116.
MurphyTJNiCNZangYMannickJALedererJA: CD41CD251 regulatory T cells control innate immune reactivity after injury. J Immunol2005; 174:2957–63.
117.
KimHMShinHYJeongHJReduced IL-2 but elevated IL-4, IL-6, and IgE serum levels in patients with cerebral infarction during the acute stage. J Mol Neurosci2000; 14:191–6.
118.
Waje-AndreassenUKrakenesJUlvestadEIL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand2005; 111:360–5.
119.
Al-BahraniATahaSShaathHBakhietM: TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. Curr Neurovasc Res2007; 4:31–7.
120.
ZarembaJLosyJ: Interleukin-18 in acute ischaemic stroke patients. Neurol Sci2003; 24:117–24.
121.
LiGZZhongDYangLMExpression of interleukin-17 in ischemic brain tissue. Scand J Immunol2005; 62:481–6.
122.
KostulasNPelidouSHKivisakkPKostulasVLinkH: Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke1999; 30:2174–9.
123.
LiHLKostulasNHuangYMIL-17 and IFN-gamma mRNA expression is increased in the brain and systemically after permanent middle cerebral artery occlusion in the rat. J Neuroimmunol2001; 116:5–14.
124.
SchroeterMJanderS: T-cell cytokines in injury-induced neural damage and repair. Neuromol Med2005; 7:183–95.
125.
VilaNCastilloJDavalosAEsteveAPlanasAMChamorroA: Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke2003; 34:671–5.
126.
YoungchaiyudUCoatesASWhittinghamSMackayIR: Cellular-immune response to myelin protein: absence in multiple sclerosis and presence in cerebrovascular accidents. Aust NZ J Med1974; 4: 535–8.
127.
KallenBNilssonOThelinC: Effect of encephalitogenic protein on migration in agarose of leukocytes from patients with multiple sclerosis. A longitudinal study of patients with relapsing multiple sclerosis or with cerebral infarction. Acta Neurol Scand1977; 55: 47–56.
128.
WangWZOlssonTKostulasVHojebergBEkreHPLinkH: Myelin antigen reactive T cells in cerebrovascular diseases. Clin Exp Immunol1992; 88: 157–62.
129.
BornsteinNMAronovichBKorczynADShavitSMichaelsonDMChapmanJ: Antibodies to brain antigens following stroke. Neurology2001; 56:529–30.
130.
DambinovaSAKhounteevGAIzykenovaGAZavolokovIGIlyukhinaAYSkorometsAA: Blood test detecting autoantibodies to N-methyl-d-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem2003; 49:1752–62.
131.
BeckerKJKindrickDLLesterMPSheaCYeZC: Sensitization to brain antigens after stroke is augmented by lipopolysaccharide. J Cereb Blood Flow Metab2005; 25:1634–44.
132.
TarkowskiENaverHWallinBGBlomstrandCTarkowskiA: Lateralization of T-lymphocyte responses in patients with stroke. Effect of sympathetic dysfunction?Stroke1995; 26:57–62.
133.
TarkowskiEJensenCEkholmSEkelundPBlomstrandCTarkowskiA: Localization of the brain lesion affects the lateralization of T-lymphocyte dependent cutaneous inflammation. Evidence for an immunoregulatory role of the right frontal cortex-putamen region. Scand J Immunol1998; 47:30–6.
134.
KochHJUyanikGBogdahnUIckensteinGW: Relation between laterality and immune response after acute cerebral ischemia. Neuroimmunomodulation2006; 13:8–12.
135.
WallinRPLundqvistAMoreSHvonBAKiesslingRLjunggrenHG: Heat-shock proteins as activators of the innate immune system. Trends Immunol2002; 23:130–5.
136.
IzakiKKinouchiHWatanabeKInduction of mitochondrial heat shock protein 60 and 10 mRNAs following transient focal cerebral ischemia in the rat. Brain Res Mol Brain Res2001; 88:14–25.
137.
OsterlohAKalinkeUWeissSFleischerBBreloerM: Synergistic and differential modulation of immune responses by Hsp60 and lipopolysaccharide. J Biol Chem2007; 282:4669–80.
MariucciGTantucciMGiudittaAAmbrosiniMV: Permanent brain ischemia induces marked increments in hsp72 expression and local protein synthesis in synapses of the ischemic hemisphere. Neurosci Lett2007; 415:77–80.
140.
ZhengZKimJYMaHLeeJEYenariMA: Anti-inflammatory effects of the 70 kDa heat shock protein in experimental stroke. J Cereb Blood Flow Metab2008; 28:53–63.
141.
van der WeerdLLythgoeMFBadinRANeuroprotective effects of HSP70 overexpression after cerebral ischaemia - an MRI study. Exp Neurol2005; 195:257–66.
142.
YenariMALiuJZhengZVexlerZSLeeJEGiffardRG: Anti-apoptotic and anti-inflammatory mechanisms of heat-shock protein protection. Ann NY Acad Sci2005; 1053:74–83.
143.
YasudaHShichinoheHKurodaSIshikawaTIwasakiY: Neuroprotective effect of a heat shock protein inducer, geranylgeranylacetone in permanent focal cerebral ischemia. Brain Res2005; 1032: 176–82.
144.
GiulianDBakerTJShihLCLachmanLB: Interleukin 1 of the central nervous system is produced by ameboid microglia. J Exp Med1986; 164: 594–604.
145.
BanatiRBRotheGValetGKreutzbergGW: Detection of lysosomal cysteine proteinases in microglia: flow cytometric measurement and histochemical localization of cathepsin B and L. Glia1993; 7:183–91.
146.
PianiDFreiKDoKQCuenodMFontanaA: Murine brain macrophages induced NMDA receptor mediated neurotoxicity in vitro by secreting glutamate. Neurosci Lett1991; 133:159–62.
147.
ChaoCCHuSMolitorTWShaskanEGPetersonPK: Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol1992; 149:2736–41.
148.
LeeJCChoGSKimHJAccelerated cerebral ischemic injury by activated macrophages/microglia after lipopolysaccharide microinjection into rat corpus callosum. Glia2005; 50: 168–81.
149.
YrjanheikkiJKeinanenRPellikkaMHokfeltTKoistinahoJ: Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA1998; 95:15769–74.
150.
RaivichGBohatschekMKlossCUWernerAJonesLLKreutzbergGW: Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res Brain Res Rev1999; 30:77–105.
151.
BeschornerRSimonPSchauerNReactive astrocytes and activated microglial cells express EAAT1, but not EAAT2, reflecting a neuroprotective potential following ischaemia. Histopathology2007; 50:897–910.
152.
IshikawaMCooperDArumugamTVZhangJHNandaAGrangerDN: Platelet-leukocyte-endothelial cell interactions after middle cerebral artery occlusion and reperfusion. J Cereb Blood Flow Metab2004; 24:907–15.
153.
ArumugamTVSalterJWChidlowJHBallantyneCMKevilCGGrangerDN: Contributions of LFA-1 and Mac-1 to brain injury and microvascular dysfunction induced by transient middle cerebral artery occlusion. Am J Physiol Heart Circ Physiol2004; 287:H2555–60.
154.
YilmazGArumugamTVStokesKYGrangerDN: Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation2006; 113:2105–12.
155.
WangXXuLWangHZhanYPureEFeuersteinGZ: CD44 deficiency in mice protects brain from cerebral ischemia injury. J Neurochem2002; 83:1172–9.
156.
SchwaningerMIntaIHerrmannO: NF-kappaB signalling in cerebral ischaemia. Biochem Soc Trans2006; 34:1291–4.
SchwartzMMoalemG: Beneficial immune activity after CNS injury: prospects for vaccination. J Neuroimmunol2001; 113:185–92.
159.
CohenIRSchwartzM: Autoimmune maintenance and neuroprotection of the central nervous system. J Neuroimmunol1999; 100:111–4.
160.
SchwartzMCohenILazarov-SpieglerOMoalemGYolesE: The remedy may lie in ourselves: prospects for immune cell therapy in central nervous system protection and repair. J Mol Med1999; 77:713–7.
161.
StollGJanderSSchroeterM: Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system. Adv Exp Med Biol2002; 513:87–113.
162.
HohlfeldRKerschensteinerMStadelmannCLassmannHWekerleH: The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. Neurol Sci2006; 27(Suppl 1): S1–7.
163.
HohlfeldR: Does inflammation stimulate remyelination?J Neurol2007; 254(Suppl 1): I47–54.
164.
HohlfeldRKerschensteinerMStadelmannCLassmannHWekerleH: The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J Neuroimmunol2000; 107:161–6.
165.
SchwartzMKipnisJ: Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries. Trends Mol Med2001; 7:252–8.
166.
HendrixSNitschR: The role of T helper cells in neuroprotection and regeneration. J Neuroimmunol2007; 184:100–12.
167.
ZhuYYangGYAhlemeyerBTransforming growth factor-beta 1 increases bad phosphorylation and protects neurons against damage. J Neurosci2002; 22:3898–909.
168.
KimYLeeC: The gene encoding transforming growth factor beta 1 confers risk of ischemic stroke and vascular dementia. Stroke2006; 37:2843–5.
169.
MoalemGGdalyahuAShaniYProduction of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J Autoimmun2000; 15:331–45.
170.
BechmannI: Failed central nervous system regeneration: a downside of immune privilege?Neuromolecular Med2005; 7:217–28.
171.
DhoddaVKSailorKABowenKKVemugantiR: Putative endogenous mediators of preconditioning-induced ischemic tolerance in rat brain identified by genomic and proteomic analysis. J Neurochem2004; 89:73–89.
172.
BowenKKNaylorMVemugantiR: Prevention of inflammation is a mechanism of preconditioning-induced neuroprotection against focal cerebral ischemia. Neurochem Int2006; 49:127–35.
173.
BernaudinMTangYReillyMPetitESharpFR: Brain genomic response following hypoxia and re-oxygenation in the neonatal rat. Identification of genes that might contribute to hypoxia-induced ischemic tolerance. J Biol Chem2002; 277:39728–38.
174.
DhoddaVKSailorKABowenKKVemugantiR: Putative endogenous mediators of preconditioning-induced ischemic tolerance in rat brain identified by genomic and proteomic analysis. J Neurochem2004; 89:73–89.
175.
ChangYCShyuWCLinSZLiH: Regenerative therapy for stroke. Cell Transplant2007; 16:171–81.
176.
ChenJLiYWangLTherapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke2001; 32:1005–11.
177.
PaczkowskaELaryszBRzeuskiRHuman hematopoietic stem/progenitor-enriched CD34(+) cells are mobilized into peripheral blood during stress related to ischemic stroke or acute myocardial infarction. Eur J Haematol2005; 75:461–7.
178.
KuciaMZhangYPRecaRCells enriched in markers of neural tissue-committed stem cells reside in the bone marrow and are mobilized into the peripheral blood following stroke. Leukemia2006; 20:18–28.
179.
AiutiAWebbIJBleulCSpringerTGutierrez-RamosJC: The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med1997; 185:111–20.
180.
CeradiniDJKulkarniARCallaghanMJProgenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med2004; 10:858–64.
181.
LoisCGarcia-VerdugoJMvarez-BuyllaA: Chain migration of neuronal precursors. Science1996; 271:978–81.
182.
ArvidssonACollinTKirikDKokaiaZLindvallO: Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med2002; 8:963–70.
183.
ParentJMVexlerZSGongCDeruginNFerrieroDM: Rat forebrain neurogenesis and striatal neuron replacement after focal stroke. Ann Neurol2002; 52:802–13.
184.
ZivYAvidanHPluchinoSMartinoGSchwartzM: Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury. Proc Natl Acad Sci USA2006; 103:13174–9.
185.
ZivYRonNButovskyOImmune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat Neurosci2006; 9:268–75.
186.
PluchinoSZanottiLRossiBNeurosphere-derived multi-potent precursors promote neuroprotection by an immunomodulatory mechanism. Nature2005; 436:266–71.
187.
DichgansM: Genetics of ischaemic stroke. Lancet Neurol2007; 6: 149–61.
188.
MintzMEpsteinLGKoenigsbergerMR: Idiopathic childhood stroke is associated with human leukocyte antigen (HLA)-B51. Ann Neurol1992; 31:675–7.
189.
HoppeCKlitzWNobleJVigilLVichinskyEStylesL: Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood2003; 101:2865–9.
190.
DeGrabaTJ: Immunogenetic susceptibility of atherosclerotic stroke: implications on current and future treatment of vascular inflammation. Stroke2004; 35:2712–9.
191.
SieMPUitterlindenAGBosMJTGF-beta 1 polymorphisms and risk of myocardial infarction and stroke: the Rotterdam Study. Stroke2006; 37:2667–71.
192.
WorrallBBBrottTGBrownRDJrIL1RN VNTR polymorphism in ischemic stroke: analysis in 3 populations. Stroke2007; 38:1189–96.
193.
Enlimomab acute stroke trial investigators Use of anti-ICAM-1 therapy in ischemic stroke: results of the enlimomab acute stroke trial. Neurology2001; 57:1428–34.
194.
KramsMLeesKRHackeWGrieveAPOrgogozoJMFordGA: Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke2003; 34:2543–8.
195.
DavalosA: Thrombolysis in acute ischemic stroke: successes, failures, and new hopes. Cerebrovasc Dis2005; 20(Suppl 2): 135–9.
196.
Martinez-VilaEIrimiaP: Challenges of neuroprotection and neurorestoration in ischemic stroke treatment. Cerebrovasc Dis2005; 20(Suppl 2): 148–58.
197.
WardNS: Mechanisms underlying recovery of motor function after stroke. Postgrad Med J2005; 81:510–4.
198.
WardNS: The neural substrates of motor recovery after focal damage to the central nervous system. Arch Phys Med Rehabil2006; 87:30–5.
199.
WardNSBrownMMThompsonAJFrackowiakRS: Longitudinal changes in cerebral response to proprioceptive input in individual patients after stroke: an FMRI study. Neurorehabil Neural Repair2006; 20:398–405.
200.
BesserMWankR: Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol1999; 162:6303–6.
201.
KerschensteinerMGallmeierEBehrensLActivated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?J Exp Med1999; 189:865–70.
202.
MuhallabSLundbergCGielenAWDifferential expression of neurotrophic factors and inflammatory cytokines by myelin basic protein-specific and other recruited T cells infiltrating the central nervous system during experimental autoimmune encephalomyelitis. Scand J Immunol2002; 55:264–73.
203.
KurozumiKNakamuraKTamiyaTMesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol Ther2005; 11: 96–104.
204.
BrycesonYTFosterJAKuppusamySPHerkenhamMLongEO: Expression of a killer cell receptor-like gene in plastic regions of the central nervous system. J Neuroimmunol2005; 161:177–82.
205.
BeckerKKindrickDMcCarronRHallenbeckJWinnR: Adoptive transfer of myelin basic protein-tolerized splenocytes to naive animals reduces infarct size: a role for lymphocytes in ischemic brain injury?Stroke2003; 34:1809–15.
206.
FrenkelDHuangZMaronRKoldzicDNMoskowitzMAWeinerHL: Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J Neurol Sci2005; 233:125–32.
207.
ZivYFinkelsteinAGeffenYA novel immune-based therapy for stroke induces neuroprotection and supports neurogenesis. Stroke2007; 38:774–82.
208.
FariaAMWeinerHL: Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol2006; 13:143–57.
209.
BakalashSShlomoGBAloniET-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure. J Mol Med2005; 83: 904–16.
210.
SerpeCJCoersSSandersVMJonesKJ: CD4+ T, but not CD8 + or B, lymphocytes mediate facial motoneuron survival after facial nerve transection. Brain Behav Immun2003; 17:393–402.
211.
DeboyCAXinJByramSCSerpeCJSandersVMJonesKJ: Immune-mediated neuroprotection of axotomized mouse facial motoneurons is dependent on the IL-4/STAT6 signaling pathway in CD4(+) T cells. Exp Neurol2006; 201:212–24.
212.
SerpeCJByramSCSandersVMJonesKJ: Brain-derived neurotrophic factor supports facial motoneuron survival after facial nerve transection in immunodeficient mice. Brain Behav Immun2005; 19:173–80.
213.
DeboyCAByramSCSerpeCJWisuriDSandersVMJonesKJ: CD4+CD25+ regulatory T cells and CD1-restricted NKT cells do not mediate facial motoneuron survival after axotomy. J Neuroimmunol2006; 176:34–8.
214.
AnkenyDPPopovichPG: Central nervous system and non-central nervous system antigen vaccines exacerbate neuropathology caused by nerve injury. Eur J Neurosci2007; 25:2053–64.
215.
LewitusGMKipnisJAvidanHBen-NunASchwartzM: Neuroprotection induced by mucosal tolerance is epitope-dependent: conflicting effects in different strains. J Neuroimmunol2006; 175: 31–8.
216.
HofstetterHHSewellDLLiuFAutoreactive T cells promote post-traumatic healing in the central nervous system. J Neuroimmunol2003; 134:25–34.
